Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aflibercept biosimilar - Sam Chun Dang Pharm

Next Previous
Drug Profile

Aflibercept biosimilar - Sam Chun Dang Pharm

Alternative Names: SCD-411

Latest Information Update: 26 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sam Chun Dang Pharm
  • Class Antineoplastics; Eye disorder therapies; Immunoglobulin Fc fragments; Immunoglobulin fragments; Recombinant fusion proteins
  • Mechanism of Action Placenta growth factor inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Wet age-related macular degeneration

Most Recent Events

  • 20 Dec 2024 Aflibercept biosimilar licensed to Fresenius Kabi in USA, Brazil, Argentina, Chile, Paraguay, Colombia, and Mexico
  • 10 Oct 2022 Aflibercept biosimilar is still in phase III trials for Wet age-related macular degeneration in Hungary, Slovakia, Poland, Bulgaria, Czech Republic, Italy (Intravitreous) (EudraCT2019-004132-37)
  • 22 Jul 2020 Phase-III clinical trials in Wet age-related macular degeneration in Hungary (Intravitreous) (EudraCT2019-004132-37)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top